Literature DB >> 19390161

Pulmonary manifestations of Sjögren's syndrome.

Ju-Hong Shi1, Hong-Rui Liu, Wen-Bing Xu, Rui-E Feng, Zhu-Hua Zhang, Xin-Lun Tian, Yuan-Jue Zhu.   

Abstract

BACKGROUND: Primary Sjögren's syndrome (PSS) is associated with various histological patterns of interstitial lung disease. Although chest images and lung function studies showed that lung involvement predominantly occurs in small airways, pathological findings were not consistent with the results of high-resolution CT (HRCT) and lung function tests.
OBJECTIVES: To investigate the pathological characteristics of PSS-associated interstitial lung disease (PSS-ILD) and their relationship with HRCT lung function tests.
METHODS: Fourteen patients diagnosed as PSS who underwent surgical lung biopsy in Peking Union Medical College Hospital from October 2000 to October 2006 were reviewed. Histopathologic findings, radiologic findings and lung function tests were analyzed.
RESULTS: The study included 13 women. The median age was 46 years. Most patients presented with dyspnea and cough. CT scans revealed bilateral ground-glass, consolidative, reticular and nodular opacities and cyst lesions. The histological patterns included nonspecific interstitial pneumonia (NSIP) cellular pattern associated with organizing pneumonia (OP), NSIP mixed pattern associated with OP, noncaseating granulomas, chronic bronchiolitis, follicular bronchiolitis, constrictive bronchiolitis, lymphocytic interstitial pneumonia associated with follicular bronchiolitis, NSIP mixed pattern associated with follicular bronchiolitis, NSIP mixed pattern coexisting with chronic bronchiolitis, OP associated with chronic bronchiolitis, and noncaseating granulomas coexisting with OP. Treatment included prednisone and cyclophosphamide. During the follow-up period (median 38 months), most patients improved or remained stable. The patient with constrictive bronchiolitis died from progression of primary disease.
CONCLUSIONS: The histopathologic patterns of PSS-ILD included lung interstitial involvement and small airway involvement or both. Corticosteroid therapy combined with cyclophosphamide was administered with a favorable response in the majority of patients.
Copyright © 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390161     DOI: 10.1159/000214841

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  19 in total

1.  Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis.

Authors:  Pieter C Goeminne; Patrick Verschueren; Hans Scheers; Lieven J Dupont
Journal:  Clin Rheumatol       Date:  2011-09-22       Impact factor: 2.980

Review 2.  Diffuse Cystic Lung Disease. Part II.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-07-01       Impact factor: 21.405

Review 3.  Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go.

Authors:  Margaret L Salisbury; Jeffrey L Myers; Elizabeth A Belloli; Ella A Kazerooni; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

Review 4.  Lung Disease in Primary Antibody Deficiencies.

Authors:  Edith Schussler; Mary B Beasley; Paul J Maglione
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

5.  A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren's syndrome-related interstitial lung disease in a Chinese population.

Authors:  Xin Dong; Junfei Zhou; Xiaojuan Guo; Yifan Li; Yuetong Xu; Qiang Fu; Yong Lu; Yi Zheng
Journal:  Clin Rheumatol       Date:  2018-09-22       Impact factor: 2.980

Review 6.  A patient with primary Sjogren's syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review.

Authors:  Leanna M Wise; Daniel G Arkfeld
Journal:  Clin Rheumatol       Date:  2019-12-20       Impact factor: 2.980

7.  Risk factors for primary Sjögren syndrome-associated interstitial lung disease.

Authors:  Yong Wang; Ziliang Hou; Meihua Qiu; Qiao Ye
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

8.  The Prevalence and clinical characteristics of primary Sjogren's syndrome patients with lung cancer: An analysis of ten cases in China and literature review.

Authors:  Yan Xu; Yunyun Fei; Wei Zhong; Li Zhang; Jing Zhao; Longyun Li; Mengzhao Wang
Journal:  Thorac Cancer       Date:  2015-01-08       Impact factor: 3.500

9.  Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases.

Authors:  Yasunori Enomoto; Tamiko Takemura; Eri Hagiwara; Tae Iwasawa; Yuh Fukuda; Noriyo Yanagawa; Fumikazu Sakai; Tomohisa Baba; Shouhei Nagaoka; Takashi Ogura
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

Review 10.  Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.

Authors:  Tihong Shao; Xiaodong Shi; Shanpeng Yang; Wei Zhang; Xiaohu Li; Jingwei Shu; Shehabaldin Alqalyoobi; Amir A Zeki; Patrick S Leung; Zongwen Shuai
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.